FDA to add vision-loss warning to GLP-1 drugs
The FDA has added a new warning label to GLP-1 drugs, a class of popular medications used for weight loss that includes Ozempic and Wegovy. The warning alerts users to a rare side effect that can cause vision loss, sometimes permanently. This is the first time the FDA has required such a warning on these drugs.
42 across the spectrum. Choose a side on the bar to jump to it.
National story. 65 articles from 44 sources. 42 are on the bar; 2 are international, entertainment or tech outlets, listed separately. Updated 4h ago.
Left
12 sourcesGLP-1 drugs must now carry warning labels about rare risk of vision loss
Taking Ozempic or Wegovy? The FDA says there’s a new warning you shouldn’t ignore
Center
23 sourcesGLP-1 drugs carry risk of rare but serious eye condition – a physician studying these medicines explains the potential side effect
Taking Ozempic or Zepbound? FDA orders warning about rare vision loss risk
Right
7 sourcesOzempic, Wegovy and Zepbound get new FDA warning over rare condition
FDA orders new warning labels on Ozempic, Wegovy over rare risk of permanent vision loss
Weight loss drugs, such as Ozempic, to carry FDA warning about rare vision-loss side effects
Other outlets
International, entertainment and tech outlets, by their rating. Not counted in the bar above. How we count coverage
Left
2 articlesFDA warns of rare eye condition causing blindness from GLP-1 weight loss medications
Center
0 articlesNone
Right
0 articlesNone
The bigger story
This story is one of several related ones. Here's where it sits.